Atenolol and Chlorthalidone
Brand Names: Atenolol and Chlorthalidone Generic
Methodology & AI Transparency ⓘ
Atenolol and Chlorthalidone Key Takeaways
Translated by Sarah Jenkins (AI RN Plain-English Translator) at a 7th-grade reading level
- 1 What it does: Indications and usage: Atenolol and chlorthalidone is indicated for the treatment of hypertension, to lower blood pressure.
- 2 Real-world patient consensus: Real-world cohort score of 75% across 14 de-identified Atenolol and Chlorthalidone entries.
- 3 Typical cash cost range: 30-day cash pricing ranges from $17.48 discount cash to $42.83 walk-in retail (NADAC $0.2217/unit).
- 4 Top reported side effects / signs: Most commonly reported Atenolol and Chlorthalidone tolerability events: dizziness (7.8%), headache (7.3%), fatigue (6.3%).
Ask our AI Specialists anything about Atenolol and Chlorthalidone
Atenolol and Chlorthalidone Mechanism, CYP450 Pathways & DailyMed Monograph
Indications and usage: Atenolol and chlorthalidone is indicated for the treatment of hypertension, to lower blood pressure. Lowering blood pressure lowers the risk of fatal and non-fatal cardiovascular events, primarily strokes and myocardial infarctions. These benefits have been seen in controlled trials of antihypertensive drugs from a wide variety of pharmacologic classes including atenolol and chlorthalidone.
CLINICAL PHARMACOLOGY Atenolol and Chlorthalidone Atenolol and chlorthalidone have been used singly and concomitantly for the treatment of hypertension. The antihypertensive effects of these agents are additive, and studies have shown that there is no interference with bioavailability when these agents are given together in the single combination tablet. Therefore, this combination provides a convenient formulation for the concomitant administration of these two entities. In patients with more severe hypertension, atenolol and chlorthalidone may be administered with other antihypertensives such as vasodilators.
Systemic exposure to Atenolol and Chlorthalidone reflects Oral fraction absorbed ranges from 46% to 58% (Atenolol and Chlorthalidone 100) absorption kinetics and dual hepatorenal clearance pathway combining glucuronidation and urinary filtration of atenolol and chlorthalidone, sustaining receptor engagement across a Mean elimination half-life of 4 to 12 hours across adult Atenolol and Chlorthalidone dosing half-life window (oral tmax achieved within 2 to 3 hours following atenolol and chlorthalidone ingestion response profile).
Dosing protocols (100 mg/1 / 25 mg/1 Tablet or 50 mg/1 / 25 mg/1 Tablet) balance efficacy (75.00% patient satisfaction across 14 logs) against dizziness (7.8% of reports), headache (7.3% of reports), fatigue (6.3% of reports), with strict avoidance in contraindications atenolol and chlorthalidone tablets are contraindicated in patients with: sinus bradycardia; heart block greater than first degree; overt cardiac failure.
Staggering Atenolol and Chlorthalidone apart from antacid or iron products prevents insoluble gastrointestinal complexation.
Verify medication reconciliation lists so Atenolol and Chlorthalidone is not inadvertently duplicated with another beta-adrenergic blocker.
Standard Adult Titration & Dosages
Absolute & Relative Contraindications
- CONTRAINDICATIONS Atenolol and chlorthalidone tablets are contraindicated in patients with: sinus bradycardia
- heart block greater than first degree
- overt cardiac failure
Logged Side-Effect Incidence (14 Reports)
Atenolol and Chlorthalidone Real-World Side Effects: openFDA FAERS vs. Patient Micro-Logs
Peer-Reviewed Human Clinical Trials & Meta-Analyses (Atenolol and Chlorthalidone)
| Study & Plain-English Finding | Sample (N) | Rigor | Primary Source |
|---|---|---|---|
| Can This Approach Help? Inside the Latest Research on Atenolol, amlodipine, enalapril, hydrochlorothiazide, and losartan for Severity of sleep-disordered breathing and well-being during the day were not significantly influenced by any of the study compounds. American journal of respiratory and critical care medicine • 2000-05-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 10806134 ↗ |
| Can This Approach Help? Inside the Latest Research on Achieved systolic blood pressure on kidney function in hypertensive Lower average on-treatment SBP (≤130 mmHg) was associated with a lower baseline eGFR but with a slower reduction in eGFR during 4-year follow-up in hypertensive patients with ECG LVH, independent of other possible risk factors... European heart journal. Quality of care & clinical outcomes • 2016-10-01 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 29474712 ↗ |
| Can This Approach Help? Inside the Latest Research on Left Ventricular Wall Stress-Mass-Heart Rate Product and heart and blood vessel Although losartan-based therapy reduced ventricular mass more, greater heart rate reduction with atenolol resulted in larger reduction of the triple product. Hypertension (Dallas, Tex. : 1979) • 2015-11-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 26418019 ↗ |
| Can This Approach Help? Inside the Latest Research on Digoxin use and risk of mortality in hypertensive patients with irregular In hypertensive patients with ECG left ventricular hypertrophy with existing or new irregular heartbeat (AFib), digoxin use is not associated with a significantly increased risk of all-cause mortality after adjusting for other... Journal of hypertension • 2015-07-15 • Randomized Controlled Trial | N = 134 | 82/100 | PMID 25799208 ↗ |
| Can This Approach Help? Inside the Latest Research on Incidence of heart failure in relation to QRS duration during Persistence or development of a prolonged QRS during blood-pressure-lowering therapy is associated with an increased likelihood of new-onset heart failure, independent of blood pressure lowering, treatment modality and... Journal of hypertension • 2009-11-15 • Randomized Controlled Trial | Multi-cohort | 82/100 | PMID 19834342 ↗ |
Atenolol and Chlorthalidone Public Price Transparency Ledger
| Dispensing Channel / Benchmark | Verification Source | Reference Cost | Details |
|---|---|---|---|
| Pharmacy Acquisition Cost (CMS NADAC) | CMS Medicaid NADAC Weekly National Survey | $0.2217/unit (~$6.65/30u) | Wholesale baseline |
| Average U.S. Walk-In Retail Cash Price | Chain Pharmacy Uninsured Cash Index | $42.83 / mo | Before coupon/insurance |
| Patient-Logged Out-of-Pocket Average | 14 Anonymous DotMD Community Micro-Logs | $17.48 / mo | View logs ↓ |
| Sesame Direct Cash-Pay Prescriber Network (Licensed Telehealth Cash Program) | State-licensed clinician review • ~1d mail fulfillment | $29.00 consult | Program details |
Atenolol and Chlorthalidone Federal Verification & Benchmark Summary
| Metric | Verified Benchmark | Source |
|---|---|---|
| Atenolol and Chlorthalidone RxNorm Concept ID | 197382 | U.S. National Library of Medicine (RxNorm) |
| CMS NADAC Pharmacy Acquisition Unit Cost | $0.2217 / unit | CMS Medicaid NADAC Weekly Feed |
| Walk-In Chain Pharmacy Cash Average | $42.83 / mo | U.S. Uninsured Retail Cash Index |
| Public Mail-Order Wholesale Benchmark | $17.48 / mo (Patient Mean) | Public Cash Reference |
| Real-World Patient Consensus | 75.00% Worth It (14 anonymous logs) | DotMD Zero-PHI Patient Ledger |
Atenolol and Chlorthalidone Patient Community, Cohort Filters & Dosage Logs
Federal clinical ledger for Atenolol and Chlorthalidone integrating DailyMed SPL (2024-03-01), CMS NADAC ($0.2217/unit), and 14 Zero-PHI patient logs.
Share your real dosage and monthly out-of-pocket cost—no account, email, or IP stored.
Filter Atenolol and Chlorthalidone community threads and patient logs by age, biological sex, dosage, and treatment duration.